Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 143Neoplasm Metastasis 16Ovarian Neoplasms 6Advanced Breast Cancer 6Prostatic Neoplasms 5Breast Cancer Metastatic 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Lobular 3Lung Neoplasms 2HER2-positive Breast Cancer 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1The Neoadjuvant Therapy 1Stomach Neoplasms 1Solid Tumor 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Sarcoma 1Salivary Gland Neoplasms 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Malignant Neoplasms of Female Genital Organs 1

Interventions

palbociclib 2Letrozole 2Fulvestrant 2pyrotinib 1Trastuzumab 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Estrogen Receptor-positive Breast Cancer × Fulvestrant × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

NCT05076695 2021-10-13

NeoTPPF

Fudan University

Phase 2 Unknown
37 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡